You are viewing the site in preview mode

Skip to main content

Advertisement

Figure 3 | BMC Infectious Diseases

Figure 3

From: Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials

Figure 3

Local and general solicited symptoms in adults. Total vaccinated cohort within 7 days after dose 1 (A) and dose 2 (B). Vertical lines show 95% CIs. Grade 3 was defined as: pain -significant pain at rest, prevented normal activities as assessed by inability to attend/do work or school: redness or swelling >100 mm; Fever: oral/axillary temperature ≥39.0°C; all other symptoms: Prevents normal everyday activities as assessed by inability to attend/do work or school, or requires intervention of a physician/healthcare provider. See Table 1 for details of treatment groups in each study.

Back to article page